

PROMOTED BY



FONDAZIONE
INTERNAZIONALE
MENARINI



3RD INTERNATIONAL SYMPOSIUM ON:
**THE CALCIUM
SENSING
RECEPTOR
(CASR)**

**Palazzo Ximènes
Panciaticchi
Florence (Italy)**

May 11th - 13th
2017



FINAL PROGRAM

ORGANIZED BY:

**UNIVERSITY
OF FLORENCE**
Florence, Italy

**MEDICAL
UNIVERSITY
OF VIENNA**
Vienna, Austria

**UNIVERSITY
OF OXFORD**
Oxford, UK

**UNIVERSITY
OF CALIFORNIA**
San Francisco CA, USA

The symposium will bring together basic, translational and clinical scientists from different disciplines who study the molecular biology, physiology, and pathophysiology of the CaSR and clinical disorders of CaSR function.

The program will feature recent research on the role of the CaSR in e.g. skeletal physiology, vascular calcification, pulmonary function, neuronal injury, parathyroid physiology, mineral metabolism, exocrine and transport functions in the gut and kidney, skin biology and cancer cell signalling. Clinical uses of CaSR modulators to treat human disorders, structural and signaling aspects of the CaSR and interactions between the CaSR and other GPCRs will be highlights.

The program will include lectures from keynote speakers, oral presentations, poster discussion sessions and forums for young investigators to meet senior experts.

**Maria Luisa Brandi, Enikő Kállay,
Rajesh V. Thakker and Wenhan Chang**
Co-Presidents of the Symposium

WITH THE ENDORSEMENTS OF

*Presidenza del Consiglio
dei Ministri*

Ministero della Salute

REGIONE
TOSCANA



UNIVERSITÀ
DEGLI STUDI
FIRENZE



Azienda
Ospedaliero
Universitaria
Careggi



PRESIDENTS OF THE MEETING

Maria Luisa BRANDI

University of Florence

Unity of Bone and Mineral Metabolism Diseases
Florence (Italy)

Enikő KÁLLAY

Medical University of Vienna

Department of Pathophysiology and Allergy Research
Vienna (Austria)

Wenhan CHANG

University of California

UCSF Endocrinology & Metabolism
Department of Medicine
San Francisco CA (USA)

Rajesh V. THAKKER

University of Oxford

Nuffield Department of Medicine
Oxford Centre for Diabetes, Endocrinology and Metabolism (OCDEM)
Churchill Hospital
Headington Oxford (UK)

INTERNATIONAL SCIENTIFIC COMMITTEE

- Hans Bräuner-Osborne
- Michael T. Collins
- Arthur Conigrave
- Rachel I. Gafni
- Edward F. Nemeth
- Dolores Shoback
- John J. Wysolmerski

PROMOTED BY

Fondazione Internazionale Menarini

Centro Direzionale Milanofiori
Edificio L – Strada 6
20089 Rozzano (Milan, Italy)
Phone: +39 02 55308110
Fax: +39 02 55305739
E-mail: milan@fondazione-menarini.it
www.fondazione-menarini.it

ORGANIZING SECRETARIAT

I&C s.r.l.

Via Andrea Costa, 202/6 - 40134 Bologna (Italy)
Phone: +39 051 6144004 Fax: +39 051 6142772
E-mail: stefania.parolari@iec-srl.it; giulia.delia@iec-srl.it
www.iec-srl.it

PROGRAMME

THURSDAY, MAY 11TH - AFTERNOON

OPENING CEREMONY

01.30 p.m.

Welcome addresses and Presentation of the 4th Parathyroid Medal of FIRMO Foundation

Maria Luisa Brandi (Florence, I)

Wenhan Chang (San Francisco CA, USA)

Enikő Kállay (Vienna, A)

Rajesh V. Thakker (Oxford, UK)

SESSION I – CALCIUM CASR SIGNALLING

Chairpersons:

Frank Bruggeman (Amsterdam, NL)

Ernesto Carafoli (Padua, I)

02.00 p.m.

Dolores Shoback (San Francisco CA, USA)

The CaSR discovery opens way to the future

02.30 p.m.

Arthur Conigrave (Sydney, AUS)

Biased signalling from CaSR

03.00 p.m.

Hans Bräuner-Osborne (Copenhagen, DK)

Trans-activation and allosteric modulation of internalization of the calcium-sensing receptor

03.30 p.m.

Donald Ward (Manchester, UK)

Cell-specific CaSR signalling: effector feedback modulation of receptor responsiveness

04.00 p.m.

Leonidas Tsiokas (Edmond OK, USA)

Regulation of CaSR by TRPC1 channels

04.30 p.m.

Coffee Break

SESSION II – PHARMACOLOGY OF THE CASR

Chairpersons:	Maria Luisa Brandi (<i>Florence, I</i>) Sandra Petraglia (<i>Roma, I</i>)
05.00 p.m.	Gerda E. Breitwieser (<i>Danville PA, USA</i>) <i>Pharmacofeatures</i>
05.30 p.m.	Edward F. Nemeth (<i>Toronto, CDN</i>) <i>Calcimimetic and Calcilytic Drugs</i>
06.00 p.m.	Letizia Vannucci (<i>Florence, I</i>) <i>Parathyroid cell lines: a model for in vitro drug testing</i>
06.30 p.m.	PLENARY LECTURE Rajesh V. Thakker (<i>Oxford, UK</i>) introduces: Allen M. Spiegel (<i>New York NY, USA</i>) <i>Calcium actions and its regulators: from basic research to clinical applications</i>
07.15 p.m.	Welcome cocktail

FRIDAY, MAY 12TH – MORNING

SESSION III – THE ROLE OF CASR IN THE PATHOGENESIS OF CALCITROPIC DISORDERS

Chairpersons:	Laura Masi (<i>Florence, I</i>) Dolores Shoback (<i>San Francisco CA, USA</i>)
08.30 a.m.	Rajesh V. Thakker (<i>Oxford, UK</i>) <i>CaSR signalling pathways and hypercalcemia in humans</i>
09.00 a.m.	Michael Mannstadt (<i>Boston MA, USA</i>) <i>CaSR and Gα11 in hypoparathyroidism in humans</i>
09.30 a.m.	Giuseppe Vezzoli (<i>Milan, I</i>) <i>Kidney disorders</i>
10.00 a.m.	David Goltzman (<i>Montreal, CDN</i>) <i>Bone diseases</i>
10.30 a.m.	Coffee break

SESSION IV - ORAL COMMUNICATIONS AND HOT TOPICS

Chairpersons:	Luisella Cianferotti (Florence, I) Geoffrey N. Hendy (Montreal, CDN)
11.00 a.m.	Caroline M. Gorvin (Oxford, UK) <i>Studies of an autosomal dominant hypocalcemia Type-1 (Adh1) associated Calcium-sensing Receptor (CaSR) mutation, ARG680GLY, provides insights into biased signalling</i>
11.15 a.m.	Martin Schepelmann (Newcastle, UK) <i>Altered mineral ion metabolism in a mouse model of targeted CaSR deletion from vascular smooth muscle cells</i>
11.30 a.m.	Sarah Howles (Oxford, UK) <i>Mice with an inactivating ASP195GLY mutation in G- protein Subunit Alpha-11 (Gα11) are a model for familial hypocalciuric hypercalcaemia type 2 (FHH2)</i>
11.45 a.m.	Polina Yarova (Cardiff, UK) <i>Towards the repurposing existing clinical-grade calcilytics for allergic asthma</i>
12.00 p.m.	Nariman Balenga (Baltimore MD, USA) <i>Orphan adhesion GPCR GPR64 regulates CaSR function in parathyroid</i>
12.15 p.m.	Marianna Ranieri (Bari, Italy) <i>A Novel CaSR-dependent microRNA pathway is involved in the downregulation of AQP2 expression contributing to volume depletion in Pendrin/NA-CL cotransporter DKO MICE</i>
12.30 p.m.	Lunch and poster discussion

FRIDAY, MAY 12TH – AFTERNOON

SESSION V - PRECLINICAL MODELS

Chairpersons:	Arthur Conigrave (Sydney, AUS) Donald Ward (Manchester, UK)
02.00 p.m.	Qing R. Fan (New York NY, USA) <i>Crystal structure of CaSR</i>
02.30 p.m.	Wenhan Chang (San Francisco CA, USA) <i>CaSR/GABABR1 heteromers mediate PTH hypersecretion in hyperparathyroidism</i>
03.00 p.m.	Fadil M. Hannan (Liverpool, UK) <i>Mouse models for ADH1 and ADH2</i>
03.30 p.m.	Caroline Gorvin (Oxford, UK) <i>Stable cell lines expressing adaptor protein 2 mutations to investigate signalling pathways</i>
04.00 p.m.	Coffee break

SESSION VI - CALCITROPIC DISORDERS: NEWS IN MEDICAL TREATMENT

Chairpersons:	Rachel I. Gafni (Bethesda MD, USA) Andrea Lenzi (Rome, I)
04.30 p.m.	John P. Bilezikian (New York NY, USA) <i>Primary hyperparathyroidism</i>
05.00 p.m.	Masafumi Fukagawa (Isehara, J) <i>Secondary hyperparathyroidism</i>
05.30 p.m.	Maria Luisa Brandi (Florence, I) <i>Hypoparathyroidism</i>
06.00 p.m.	Michael T. Collins (Bethesda MD, USA) <i>Treatment for ADH1 in humans</i>

SESSION VII – NON CALCITROPIC DISORDERS: DIGESTIVE AND SKIN FUNCTION

Chairpersons:	Enikő Kállay (Vienna, A) Francesco Tonelli (Florence, I)
06.30 p.m.	Chia-Ling Tu (San Francisco CA, USA) <i>Role of CaSR in skin wound healing</i>
07.00 p.m.	James J. Pestka (East Lansing MI, USA) <i>Control of gastroenteric hormones by CaSR</i>
07.30 p.m.	Sam Cheng (Gainesville FL, USA) <i>The role of the CaSR in gastrointestinal inflammation</i>

SATURDAY MAY 13TH - MORNING

SESSION VIII – NON CALCITROPIC DISORDERS: BLOOD VESSELS AND LUNG

Chairpersons:	Dolores Shoback (San Francisco CA, USA) Elisabetta Cerbai (Florence, I)
08.00 a.m.	Harry Z.E. Greenberg (London, UK) <i>Vasolidation NO/CaSR</i>
08.30 a.m.	Y.S. Prakash (Rochester MN, USA) <i>Calcium sensing receptor in perinatal airway disease</i>

SESSION IX – NON CALCITROPIC DISORDERS: CANCER

Chairpersons:	Wenhan Chang (San Francisco CA, USA) Romuald Mentaverri (Amiens, F)
09.00 a.m.	John J. Wysolmerski (New Haven CT, USA) <i>CaSR actions on PTHrP in breast cancer</i>
09.30 a.m.	Enikő Kállay (Vienna, A) <i>The role of the CaSR in colon cancer</i>
10.00 a.m.	Carmen de Torres (Barcelona, E) <i>The role of the CaSR in neuroblastoma</i>
10.30 a.m.	Coffee break

SESSION X – FUTURE DEVELOPMENTS FOR CASR TARGETED THERAPIES

Chairpersons:	Hans Bräuner-Osborne (Copenhagen, DK) Fadil M. Hannan (Liverpool, UK)
11.00 a.m.	Daniela Riccardi (Cardiff, UK) <i>Asthma</i>
11.30 p.m.	Seiji Fukumoto (Tokushima, J) <i>Glucose metabolism</i>
12.00 p.m.	Katie Leach (Melbourne, AUS) <i>Rational design of CaSR therapeutics for diverse disorders</i>
12.30 p.m.	Lunch and poster discussion
03.00 p.m.	CONCLUDING REMARKS Maria Luisa Brandi (Florence, I) Wenhan Chang (San Francisco CA, USA) Enikő Kállay (Vienna, A) Rajesh V. Thakker (Oxford, UK)



ASBMR YOUNG INVESTIGATOR AWARD WINNERS

- 1 Albar Halah
Signal crosstalk between CaSR and gs-coupled receptors
- 2 Brennan Sarah
Molecular requirements for temperature dependent changes in CaSR-induced Ca²⁺i oscillations
- 3 Di Mise Annarita
CaSR is functionally expressed in conditionally immortalized proximal tubular epithelial cells (ciptec) deficient for polycystin 1 or derived from ADPKD1 patients, representing a possible therapeutic target
- 4 Gluck Anna
Systematic in silico evaluation of rare genetic variants in g-protein alpha 11
- 5 Gorvin Caroline M. *ASBMR Young investigator high achievement award*
Studies of an autosomal dominant hypocalcemia type-1 (adh1) associated calcium-sensing receptor(casr) mutation, ARG680GLY, provides insights into biased signalling
- 6 Howles Sarah
Mice with an inactivating ASP195GLY mutation in g- protein subunit alpha-11 (g α 11) Are a model for familial hypocalciuric hypercalcaemia type 2 (fhh2)
- 7 Olesen Mie Kronborg
Extracellular domain calcium- sensing receptor (casr) mutations leading to hypercalcemic and hypocalcemic disorders cluster at the homodimeric interface
- 8 Sharma Preeti
CaSR protein expression analysis in stem cells derived from human skeletal muscle and human adipose tissue
- 9 Schepelmann Martin
Altered Mineral Ion Metabolism In A Mouse Model Of Targeted CaSR Deletion From Vascular Smooth Muscle Cells

GENERAL INFORMATION

Meeting venue

The venue for the Meeting will be Palazzo Ximènes Panciatichi,
Via Borgo Pinti, 68 - 50121 Florence (Italy)

Accommodation

It is possible to book a room at a special rate using the Florence Convention Bureau website (<http://www.florencecongressbooking.com/index/en.shtml>) indicating the code CASR2017.

Secretariat during the Meeting

The Secretariat will be open at the following times:
Thursday, May 11TH, from 01.30 p.m. to 07.45 p.m.
Friday, May 12TH, from 08.00 a.m. to 08.00 p.m.
Saturday, May 13TH, from 08.00 a.m. to 01.30 p.m.

Official language

The official language of the Meeting will be English.

Registration

The Meeting is free to attend.
Please confirm the participation to the Organizing Secretariat
(Fondazione Internazionale Menarini – Phone: +39 02 55308110 –
Fax: +39 02 55305739. E-mail: milan@fondazione-menarini.it)
within April 28, 2017.

Technical facilities speakers

Facilities will be available for computer presentations and overhead projections. A business center with PC (Powerpoint for Windows) will be available for check and preview of presentations. It is essential that speakers take their presentations to the business center at least one hour before the session starts.

The slide center will be open at the following times:

Thursday, May 11TH, from 01.30 p.m. to 07.45 p.m.

Friday, May 12TH, from 08.00 a.m. to 08.00 p.m.

Saturday, May 13TH, from 08.00 a.m. to 01.30 p.m.

Lunches and coffee breaks

Lunches and coffee breaks will be served in the Meeting area.

Abstracts book

Participants will receive the Abstract book at the Meeting.

European CME Credits

EACCME credits have been requested for May 11TH-12TH-13TH for the following disciplines: Internal Medicine, Metabolic and Diabetes Diseases, Rheumatology, Clinical Biochemistry, Endocrinology, Andrology and Reproduction Medicine.

EACCME credits



The '3rd International Symposium on: The Calcium-Sensing Receptor (CaSR)' was granted 12 European CME credits (ECMEC) by the European Accreditation Council for Continuing Medical Education (EACCME). Event code: 15527

The '3rd International Symposium on: The Calcium-Sensing Receptor (CaSR)' is accredited by the European Accreditation Council for Continuing Medical Education (EACCME) to provide the following CME activity for medical specialists. The EACCME is an institution of the European Union of Medical Specialists (UEMS), www.uems.net.

The '3rd International Symposium on: The Calcium-Sensing Receptor (CaSR)' is designated for a maximum of (or "for up to") 12 hours of European external CME credits. Each medical specialist should claim only those hours of credit that he/she actually spent in the educational activity.

Through an agreement between the European Union of Medical Specialists and the American Medical Association, physicians may convert EACCME credits to an equivalent number of AMA PRA Category 1 Credits™. Information on the process to convert EACCME credit to AMA credit can be found at www.ama-assn.org/go/internationalcme.

Live educational activities, occurring outside of Canada, recognized by the UEMS-EACCME for ECMEC credits are deemed to be Accredited Group Learning Activities (Section 1) as defined by the Maintenance of Certification Program of The Royal College of Physicians and Surgeons of Canada.

EACCME credits

Each medical specialist should claim only those hours of credit that he/she actually spent in the educational activity. The EACCME credit system is based on 1 ECMEC per hour with a maximum of 3 ECMECs for half a day and 6 ECMECs for a full-day event.

LIST OF CHAIRPERSONS, SPEAKERS, CO-PRESIDENTS OF THE SYMPOSIUM

John P. BILEZIKIAN

Columbia University College
of Physicians & Surgeons
Department of Medicine Division
of Endocrinology Metabolic
Bone Diseases Unit
New York Presbyterian Hospital
New York NY (USA)

Maria Luisa BRANDI

University of Florence
Unity of Bone and Mineral
Metabolism Diseases
Florence (Italy)

Hans BRÄUNER-OSBORNE

University of Copenhagen
Department of Drug Design and
Pharmacology
Faculty of Health and Medical Sciences
Copenhagen (Denmark)

Gerda E. BREITWIESER

Weis Center for Research/Geisinger
Clinic/Molecular and Functional
Genomics
Danville PA (USA)

Frank BRUGGEMAN

University of Amsterdam
Amsterdam (The Netherlands)

Ernesto CARAFOLI

University of Padua
Venetian Institute of Molecular Medicine
Padua (Italy)

Elisabetta CERBAI

University of Florence
Department of Neurosciences,
Psychology,
Drug Research and Child
Health (NEUROFARBA)
Florence (Italy)

Wenhan CHANG

University of California
UCSF Endocrinology & Metabolism
Department of Medicine
San Francisco CA (USA)

Sam CHENG

University of Florida
Department of Pediatrics
Gainesville FL (USA)

Luisella CIANFEROTTI

University of Florence
Department of Surgery and
Translational Medicine
Unit of Bone and Mineral Diseases
Florence (Italy)

Michael T. COLLINS

National Institutes of Health
Section on Skeletal Disorders
and Mineral Homeostasis
National Institute of Dental
and Craniofacial Research
Bethesda MD (USA)

Arthur CONIGRAVE

University of Sydney
Faculty of Medicine
Sydney (Australia)

Carmen DE TORRES

Hospital Sant Joan de Déu
Department of Oncology
Barcelona (Spain)

Qing Rong FAN

Columbia University
Department of Pharmacology
New York NY (USA)

Masafumi FUKAGAWA

Tokai University School of Medicine
Isehara (Japan)

Seiji FUKUMOTO

Tokushima University
Fujii Memorial Institute
of Medical Sciences
Tokushima (Japan)

Rachel I. GAFNI

National Institutes of Health
Section on Skeletal Disorders
and Mineral Homeostasis
National Institute of Dental
and Craniofacial Research
Bethesda MD (USA)

David GOLTZMAN

McGill University
McGill University Health Centre
Calcium Research Lab
Montreal (Canada)

Caroline GORVIN

University of Oxford
Academic Endocrine Unit
Oxford (United Kingdom)

Harry Z.E. GREENBERG

St George's University of London
London (United Kingdom)

Fadil M. HANNAN

University of Liverpool
Institute of Ageing and Chronic Disease
Liverpool (United Kingdom)

Geoffrey N. HENDY

McGill University
Department of Physiology and
Human Genetics
Montreal, Canada

Enikő KÁLLAY

Medical University of Vienna
Department of Pathophysiology
and Allergy Research
Vienna (Austria)

Katie LEACH

Monash University
Monash Institute of Pharmaceutical
Sciences
Melbourne (Australia)

Andrea LENZI

Department of Experimental Medicine
Sapienza University of Rome
Policlinico Umberto I
Rome (Italy)

Michael MANNSTADT

Endocrine Unit
Harvard Medical School
Massachusetts General Hospital,
Boston MA (USA)

Laura MASI

University Hospital AOU-Careggi
Metabolic Bone Diseases Unit
Florence (Italy)

Romuald MENTAVERRI

Universitary research Center
in Health (CURS)
CHU Amiens
Amiens (France)

Edward F. NEMETH

Independent Consultant
Toronto (Canada)

James J. PESTKA

Michigan State University
Department of Food Science
and Human Nutrition
East Lansing MI (USA)

Sandra PETRAGLIA

Director Bureau Independent Research
AIFA

Yedatore S. PRAKASH

Mayo Clinic
Physiology and Biomedical Engineering
Rochester MN (USA)

Daniela RICCARDI

Cardiff University
School of Biosciences
Cardiff (United Kingdom)

Dolores SHOBACK

University of California
Endocrine Section
San Francisco CA (USA)

Allen M. SPIEGEL

Albert Einstein College of Medicine
Montefiore Medicine
New York NY (USA)

Rajesh V. THAKKER

University of Oxford
Nuffield Department of Clinical
Medicine, OCDEM
Churchill Hospital
Headington, Oxford (UK)

Francesco TONELLI

General Surgery
University of Florence
Florence (Italy)

Leonidas TSIOKAS

Department of Cell Biology
Regulation of CaSR function
by the TRPC1 channel
University of Oklahoma
Health Sciences Center
Oklahoma City, OK (USA)

Chia-ling TU

Department of Medicine
University of California
Endocrine Research Unit
San Francisco VA Medical Center
San Francisco CA (USA)

Letizia VANNUCCI

University of Florence
Unity of Bone and Mineral
Metabolism Diseases
Florence (Italy)

Giuseppe VEZZOLI

San Raffaele Scientific Institute
Nephrology and Dialysis Unit
Milan (Italy)

Donald WARD

University of Manchester
Faculty of Biology, Medicine and Health
Manchester (United Kingdom)

John J. WYSOLMERSKI

Section of Endocrinology and
Metabolism
Department of Internal Medicine
Yale School of Medicine
New Haven CT (USA)

I r qgd} Ir qh#l qwud} Ir qdñ#P hquql
VI p sr vld=666

